Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2020 pubmed 67 citations

Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model.

Yang. Xu X; Guo. Jing-Lin JL; Han. Jing J; Si. Rui-Juan RJ; Liu. Pan-Pan PP; Zhang. Zi-Rui ZR; Wang. Ai-Min AM; Zhang. Ju J

Key Findings

  • LL‑37/chitosan hydrogel was non‑toxic to fibroblasts and reduced TNF‑α release from activated macrophages.
  • At 5 µg/mL the formulation inhibited growth of Staphylococcus aureus.
  • Mice with pressure ulcers treated with LL‑37/chitosan gel showed significantly smaller ulcer areas and increased markers of angiogenesis (HIF‑1α, VEGF‑A).

Practical Outcomes

  • For DIY wound‑care enthusiasts, the data suggest that a chitosan‑based carrier could protect LL‑37 from degradation and make it more effective as a topical anti‑infection and healing agent. However, the work is still in mice, so human dosing, safety, and regulatory issues remain unresolved. Until clinical trials appear, using LL‑37 in a chitosan gel should be considered experimental and limited to controlled research settings.

Summary

A study in mice showed that putting the antimicrobial peptide LL‑37 into a chitosan gel makes the gel safe for skin cells, cuts inflammation, kills Staph bacteria, and speeds up healing of pressure sores. The treated wounds were smaller, had thicker skin layers and more new blood vessels compared with untreated or gel‑only controls.

Abstract

LL-37 peptide is a member of the human cathelicidin family, and has been shown to promote the healing of pressure ulcers. However, the low stability of this peptide within the wound environment limits its clinical use. Chitosan (CS) hydrogel is commonly used as a base material for wound dressing material. CS hydrogel (2.5% w/v) was encapsulated with LL-37. Cytotoxicity of the product was examined in cultured NIH3T3 fibroblasts. Effects on immune response was examined by measuring tumor necrosis factor-α (TNF-α) release from RAW 264.7 macrophages upon exposure to lipopolysaccharides. Antibacterial activity was assessed using Staphylococcus aureus. Potential effect on pressure ulcers was examined using a mouse model. Briefly, adult male C57BL/6 mice were subjected to skin pressure using magnets under a 12/12 h schedule for 21 days. Mice were randomized to receive naked LL-37 (20 μg), chitosan gel containing 20-μg LL-37 (LL-37/CS hydrogel) or hydrogel alone under the ulcer bed (n = 6). A group of mice receiving no intervention was also included as a control. LL-37/CS hydrogel did not affect NIH3T3 cell viability. At a concentration of 1-5 μg/ml, LL-37/CS inhibited TNF-α release from macrophage. At 5 μg/ml, LL-37/CS inhibited the growth of Staphylococcus aureus. The area of the pressure ulcers was significantly lower in mice receiving LL-37/CS hydrogel in comparison to all other 3 groups on days 11 (84.24% ± 0.25%), 13 (56.22% ± 3.91%) and 15 (48.12% ± 0.28%). Histological examination on days 15 and 21 showed increased epithelial thickness and density of newly-formed capillary with naked LL-37 and more so with LL-37/CS. The expression of key macromolecules in the process of angiogenesis (i.e., hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor-A (VEGF-A)) in wound tissue was increased at both the mRNA and protein levels. Chitosan hydrogel encapsulated with LL-37 is biocompatible and could promote the healing of pressure ulcers.

Study Information

Provider

pubmed

Year

2020

Date

2020-04-22T00:00:00.000Z

DOI

10.1186/s40779-020-00249-5

Citations

67

References

45